about
Treatment strategies for chronic hepatitis C prior to and following liver transplantationModel for End-stage Liver DiseaseIschemia/reperfusion, does temperature matter? Laboratory perspective.Big data in organ transplantation: registries and administrative claims.Reexamining the Association of Body Mass Index With Overall Survival Outcomes After Liver TransplantationImpact of broader sharing on the transport time for deceased donor liversExtended postinterventional tumor necrosis-implication for outcome in liver transplant patients with advanced HCC.Standardizing MELD Exceptions: Current Challenges and Future DirectionsPotential role of the donor in hepatocellular carcinoma recurrence after liver transplantation.Postoperative resource utilization and survival among liver transplant recipients with Model for End-stage Liver Disease score ≥ 40: A retrospective cohort study.Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.Liver sharing and organ procurement organization performance under redistricted allocationDelayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United StatesImpact of MELD Allocation System on Waiting List and Early Post-Liver Transplant Mortality.Does Social Capital Explain Community-Level Differences in Organ Donor Designation?Effects of the Share 35 Rule on Waitlist and Liver Transplantation Outcomes for Patients with Hepatocellular Carcinoma.Exception point applications for 15 points: an unintended consequence of the share 15 policy.Addressing geographic disparities in liver transplantation through redistricting.Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.Current Status of Liver Allocation in the United StatesLiver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome.United Network for Organ Sharing regional variations in appeal denial rates with non-standard Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease exceptions: support for a national review board.HCC patients suffer less from geographic differences in organ availabilityIdentification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.Patient-reported outcomes in liver transplant recipients with hepatocellular carcinoma.Experience Since MELD Implementation: How Does the New System Deliver?Resection and transplantation for hepatocellular carcinoma: factors influencing surgical options.Review article: liver transplantation for hepatocellular carcinoma - a critical appraisal of the current worldwide listing criteria.Geographic Disparities in Liver Availability: Accidents of Geography, or Consequences of Poor Social Policy?Model for end-stage liver disease score and MELD exceptions: 15 years later.Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: Where do we stand with tumor down-staging?Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals.Geographic variation in liver transplantation persists despite implementation of Share35.Disparities in Waitlist and Posttransplantation Outcomes in Liver Transplant Registrants and Recipients Aged 18 to 24 Years: Analysis of the UNOS Database.Are geographic differences in transplantation inherently wrong?Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list.Nonstandard Exception Requests Impact Outcomes for Pediatric Liver Transplant Candidates.The Impact of Redistricting Proposals on Health Care Expenditures for Liver Transplant Candidates and Recipients.Disparities in Eurotransplant liver transplantation waitlist outcome between patients with and without exceptional MELD.Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.
P2860
Q26771244-D863537A-58FB-457E-AF80-48B233221D66Q26864971-478AEFC6-2898-4BFD-B9FD-875D38ABB3F2Q30278761-67D64FD9-F4E1-4BBB-A7FA-7CAE141700E8Q30837288-758BB7CA-518E-4DE1-81EB-61B5CDC680F8Q33874003-BE38D426-47FA-4C47-A686-91870D86E094Q34254902-D8F8091D-88CA-4D84-951B-61E3E275ADC4Q34562491-6718408B-FFEA-439D-8502-9625A530D9EEQ34712729-4866F572-138A-4C7A-8EDA-DD77C7941D75Q35020079-30113502-0063-46DB-A9FA-ED2830850947Q35647592-4F428FBB-1E3F-49AB-81A5-6628409459A2Q35869964-16B24901-B504-432A-8B86-9677FA5B5B2DQ35893880-54B0195B-0806-46F3-86F6-0885D55B3BB3Q35991480-E23DEEF4-8EE2-4AB8-8600-CD8F2229AEBDQ36051596-C1CA8471-DCF7-4165-B2EC-93AEC929EE3AQ36054092-54CCD7B6-B157-41B4-95D6-BAEE7591A898Q36259729-87B54291-C116-4D61-B652-6C411C0EF71CQ36357022-BA5DA012-9526-4CBC-A085-C4E9870CA0B9Q36359189-193F0498-86B3-4B15-8AF8-A12E65A7465CQ36728731-71C5D3A6-33AE-492E-977E-2D1A43168389Q36916627-98A23818-A231-475E-925A-FB0D254522A1Q36962089-6111EBC3-508E-42F7-A42C-403610839E5DQ37225010-1A926576-0C1B-4645-8130-63E0708EB4CDQ37323728-26C9E43D-6C52-49C5-887C-3EA8368FC4ABQ37444760-38046879-78C2-43F8-BF27-7C4ED26E7889Q37611108-F982A0F9-495F-4242-A6B3-B8582011ED50Q38054733-27BAB402-8543-4743-AD3C-EA82EC335A0FQ38206274-34746DA9-A000-48C5-B44C-F6621B5A4B23Q38243059-A460728E-7D19-451E-93CD-B4A2DB1F0033Q38371545-44E9F45E-4BAD-41AA-AF31-18E7BC5D28E4Q38504284-2DEBAF45-012E-4704-8E88-EF656D9D7072Q38631276-BA776700-E94D-4BCD-83EA-87D7951E9CE7Q38716554-03198557-0F3C-4EC4-A897-87640730F7B0Q38730876-2B69A218-D2D2-4A8A-8924-5807646662AEQ38754147-9449D999-C7BB-4AB0-820F-B486111878CDQ38984390-94104F16-3C7A-4BD1-B0F9-2DDEF868AA08Q39139767-515A34BD-154E-45D6-908D-A88C2D44C3C3Q39743527-C501AE7B-DD14-493B-9337-98CD7178F04EQ40095028-67EADD2A-4657-4802-934F-84A436468E4BQ40145699-E798BB74-8849-4780-8DAA-F34FE6BDDB7BQ40309524-9DA18E8D-22EA-4314-9A8A-96E15DEE33C1
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
MELD Exceptions and Rates of Waiting List Outcomes.
@ast
MELD Exceptions and Rates of Waiting List Outcomes.
@en
type
label
MELD Exceptions and Rates of Waiting List Outcomes.
@ast
MELD Exceptions and Rates of Waiting List Outcomes.
@en
prefLabel
MELD Exceptions and Rates of Waiting List Outcomes.
@ast
MELD Exceptions and Rates of Waiting List Outcomes.
@en
P2093
P2860
P1476
MELD Exceptions and Rates of Waiting List Outcomes
@en
P2093
A B Massie
A Gheorghian
K L Lentine
M A Schnitzler
P R Salvalaggio
S E Gentry
P2860
P304
P356
10.1111/J.1600-6143.2011.03735.X
P407
P577
2011-09-15T00:00:00Z